Heart-Healthy Rehab for Cardiac Amyloidosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Researchers will enroll adults with cardiac ATTR amyloidosis and have them complete a 5-week, daily rehabilitation program with aerobic and strength training. Before starting and about three months after completion, participants will undergo a cardiopulmonary exercise test, a non-invasive heart function assessment, and quality-of-life questionnaires to measure changes. The study uses a single-group design, comparing results within each participant from baseline to follow-up. The goal is to see if the program is feasible, safe, and beneficial for functional ability and life impact in this population. Conducted at an expert center in Montpellier, the study relies on a multidisciplinary team and standardized testing to evaluate outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 18 or older
* Cardiac ATTR amyloidosis diagnosed according to guidelines: Perugini grade II or III uptake on bone scintigraphy, without monoclonal gammopathy.
* Ability to undergo a stress test
* Available to complete the 5-week rehabilitation program within 30 days of the stress test

Exclusion Criteria:

* Uncontrolled ventricular arrhythmias
* NYHA Class IV heart failure
* Inability to give informed consent to participate in the study
* Inability to monitor the patient during the study period
* Subject not enrolled in a social security program or not eligible for such a program
* Pregnant or breastfeeding women, patients unable to give consent, protected adults, vulnerable persons
* Subjects deprived of liberty by judicial or administrative decision

Where it's running

• Krief
  Montpellier, France Recruiting

Study contacts

• Study coordinator: Susan Martinez, PhD
• Email: s-martinezjahnke@chu-montpellier.fr
• Phone: 04 67 33 52 56

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Acoramidis for ATTR-CM: Cardiac Imaging Study

  This study tests whether acoramidis can improve heart structure and function in people with transthyretin amyloid cardiomyopathy.

  Recruiting Phase 4 Eidos Therapeutics, a BridgeBio company · St Louis, Missouri · NCT07695701

• SCTC21C plus bortezomib, cyclophosphamide and dexamethasone for newly diagnosed systemic light-chain (AL) amyloidosis

  This trial tests whether adding SCTC21C to standard bortezomib‑cyclophosphamide‑dexamethasone (VCd) helps people with newly diagnosed AL (light‑chain) amyloidosis achieve better hematologic responses and outcomes.

  Recruiting Phase 3 Sinocelltech Ltd. · Beijing, Beijing Municipality · NCT07388602

• In-home cancer treatment with remote specialist support for patients in the Florida Panhandle

  This program will try giving standard cancer treatments at home to people living in the Florida Panhandle and nearby areas to see if they prefer it and have better treatment satisfaction.

  Recruiting Phase 2 Mayo Clinic · Jacksonville, Florida · NCT07285044

• 18F‑FT8 PET imaging for light‑chain (AL) cardiac amyloidosis

  This project tests whether a new PET tracer, 18F‑FT8, can safely and clearly image light‑chain (AL) cardiac amyloidosis in adults with suspected or known disease and in healthy volunteers.

  Recruiting at 3 sites Tianjin Medical University · Hefei, Anhui and 2 other locations · NCT07232459

• Belantamab Mafodotin with a chemotherapy combo for newly diagnosed AL amyloidosis

  This study tests whether adding belantamab mafodotin to a regimen of cyclophosphamide, bortezomib, and dexamethasone can help adults with newly diagnosed AL amyloidosis.

  Recruiting at 16 sites Phase 2 GlaxoSmithKline · Los Angeles, California and 15 other locations · NCT07224672

• Magnetocardiography for Cardiac Amyloidosis

  This project tests whether magnetocardiography (MCG) can help diagnose and monitor heart involvement in adults with amyloidosis compared with ECG and other standard tests.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT07218705

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.